A self-contained fiber-optic immunosensor was developed to measure the 16 500-Da protein myoglobin. The sensing element was constructed by entrapment of Cascade Blue-labeled antibody within polyacrylamide gel at the distal face of an optical fiber 300 m in core diameter. The polyacrylamide gel composition was optimized to allow diffusion of myoglobin but to exclude hemoglobin and higher-molecular-mass proteins from the sensing area. The analytical signal was derived from fluorescence energy transfer between Cascade Blue and the heme group of myoglobin. Fluorescence quenching occurred when myoglobin bound to labeled antibody. The total amount of fluorescence quench was dependent on the antibody labeling conditions and the amount of antibody incorporated in the sensor gel matrix. Myoglobin concentrations >5 nmol/L (83 g/L) were measurable with response times of 15 to 130 min limited by diffusion into the sensing element. This report demonstrates the technical feasibility for a selfcontained immunosensor to measure a protein analyte.
In vitro laboratory testing provides information after some delay for the collection and measurement process and only at discrete sampling times. Critical diagnostic and therapeutic monitoring situations may require frequent testing with short turnaround times. The need for rapid test results has led to the development of point-ofcare devices incorporating biosensor technology to bring the laboratory closer to the patient. Continuous in vivo concentration monitoring may substantially improve the care for patients who require rapid laboratory results for clinical management in acute-care environments. Continuous monitoring sensors have unique analytical attributes. They are self-contained, operate without replenishment or regeneration of reagents, provide a reversible response to changes in analyte concentration, and have a response time and operational lifetime suitable for the clinical situation. In vivo applications present additional challenges for sterility and biocompatibility. Continuous monitoring technology can also be applied to measurements for in vitro laboratory instrumentation and pointof-care devices and for monitoring the bioproduction of drugs, cell cultures, and environmental contaminants.
Biosensor measurements of specific analytes within complex sample matrices have utilized a variety of chemical indicator systems, including organic molecules, enzymes, antibodies, and receptors to isolate the desired analyte from the sample milieu with high specificity [1] [2] [3] . The recognition event usually does not generate a measurable signal in situ and therefore requires coupling to a transduction system. A variety of electrochemical and optical transduction systems have been explored to quantitate various analytes. Optical sensors have the desirable attributes of immunity to electrical noise, no risk of electrical shock to the patient, and physical flexibility, including catheter placement, to reach remote locations.
Sensor systems with antibodies for molecular recognition can be applied to a large variety of analytes. Previously reported self-contained immunosensors have measured low-molecular-mass analytes. Bush and Rechnitz [4] used an electrochemical transducer with a membraneencapsulated antibody indicator system to quantitate dinitrophenol. Anderson and Miller [5] and Hanbury et al. [6] described a continuously monitoring fiber-optic immunosensor with a fluorescence transduction system and a membrane-encapsulated competitive-binding antibody system to measure aqueous phenytoin and theophylline concentrations. Astles and Miller [7] reported the continuous measurement of phenytoin in serum and whole blood with this sensor design. Various other fiber-optic sensor designs have used antibody or enzyme transduction chemistry covalently attached to an optical fiber [8] , attached to an optical component interrogated by the fiber [9] , incorporated into a polymer matrix [10] , or temporally released from polymer gels [11] . Antibody-based sensors for measuring large protein analytes have not been selfcontained and thus have not been suitable for continuous monitoring applications [12, 13] .
One of the challenges for fiber-optic immunosensor construction is the development of a self-contained packaging design for the chemical indicator system that isolates the analyte of interest from the sample matrix. The design of reagent immobilization at the sensing area must maintain the functional activity of the recognition element and provide selective permeability for the desired analyte without excessively increasing sensor response time. Previous work from this laboratory reported a self-contained immunosensor for measurement of low-molecular-mass analytes [5] [6] [7] .
We report the development of an antibody-based fiberoptic immunosensor to measure a protein analyte. Myoglobin was an excellent model protein analyte because its moderate molecular dimensions, 16 500 Da, allowed diffusion through immobilization media, and the heme group has a large molar absorptivity that could be exploited in a fluorescence energy transfer design.
Myoglobin and other cardiac proteins have clinical relevance because they are measurable at the time of admission to the emergency department after myocardial infarction [14] . Recent advances in the treatment of acute coronary syndromes and assessment of thrombolytic therapy have demonstrated the importance of rapid assessment of patients presenting to the emergency department with chest pain [15] . One can speculate that availability of a catheter-based sensor for two or three cardiac proteins could accelerate effective therapeutic intervention in this critical condition. Coagulation proteins during surgery represent another acute-care situation in which in vitro measurement might be useful.
Materials and Methods instruments
Because of spectral interferences from conjugated fluorescent labels, protein concentrations were derived from total nitrogen measurement with a chemiluminescent pyroreactor (Antek Instruments) calibrated with ammonium sulfate calibrators. Protein concentrations were calculated by assuming 6.25 g of protein/g of nitrogen [16] .
Conventional fluorescence measurements of Cascade Blue were performed in a 1 ϫ 1 cm quartz cuvette at room temperature with a spectrofluorometer (MPF-44A, Perkin-Elmer) with a 150 W xenon arc lamp source. An excitation wavelength of 375 nm and emission wavelength of 425 nm were used for Cascade Blue. Approximately equal width slits (Ͻ4-nm band pass) were used to achieve full-scale deflection on a chart recorder. All reagent additions and mixing by volume exchange with a transfer pipette were performed manually without removing the cuvette from the sample compartment. Figure 1 shows a diagram of the fiber-optic fluorometer constructed in this laboratory. All optical components were mounted on a 14.2 ϫ 9.4 cm optical table (XI-23, Newport Research). Excitation radiation was from a 75 W xenon arc lamp (75XBO75/2OF, Osram) mounted horizontally within a f/4.5 elliptical reflector in an air-tight, water-cooled housing (HH150, Photon Technology) with a constant-current power supply (LPS 200X, Photon Technology) operated at 5 A. Excitation light was passed through a heat-absorbing glass filter; a 370-nm, 6-nm band pass filter (PIO 370-F, Corion Corp.); and then through a 2-mm hole in the central axis of a 66-mm off-axis parabolic mirror (02POA015, Melles Griot) mounted in a three-plane adjustable mount. Light passing through the mirror was collimated with a 50-mm diameter, 76-mm focal length, fused-silica biconvex lens (01LDX145, Melles Griot), and refocused on an optical fiber with a 25-mm diameter, f/1 fused-silica biconvex lens (01LQB028, Melles Griot). The lenses were arranged so that the bright spot of the lamp was at the focal point of the first lens, with the light traversing ϳ40 mm between the two lenses, after which the image of the lamp was refocused on the proximal end of an optical fiber. A five-axis fiber-optic positioner (FP-2, Newport) was used to align the optical fiber at the focal point.
fiber-optic fluorometer
Excitation light passed through ϳ1 m of multimode step-index optical fiber (320-m diameter core, 32.5-m cladding, and 385-m diameter total) with polyimide coating (Superguide G, Thermocoat, SFS320/385T, Fiberguide Industries). This fiber had negligible fluorescence at 425 nm when excited at 370 nm. The polyimide protective coating was removed from ϳ30 mm at each end of the optical fiber by charring with a butane burner, followed by cleaning with deionized water and acetone. Both ends of the optical fiber were cleaved at 90°to the longitudinal optical axis with a diamond edge cleaver (FK-LDF, York Technology), cleaned in 50 mL/L nitric acid for 15 min, soaked in a silanizing reagent (SL-2, Sigmacote, Sigma) for 5 min to block free hydroxyl groups, and rinsed with deionized water before use. Clinical Chemistry 43, No. 11, 1997 Fluorophore emission that entered the distal end of the waveguide was transmitted back through the fiber, collimated by the input lens, and reflected 90°and focused by the parabolic mirror through a 5-nm band pass entrance slit of a grating monochrometer (PTR Optics) set at 425 nm, and through a 425-nm, 5-nm band pass interference filter (XMM-425-F, Corion). The signal was detected with a photomultiplier tube (1P28B22, RCA) operated at Ϫ650 V dc (Stanford Research Systems) and measured with an analog display photon counter (126, Pacific Instruments). To prevent photodegradation of the reagents, incident light was blocked with a mechanical shutter that was opened only during data collection. Fluorometer components were aligned along the excitation optical axis with the incident arc lamp beam. A helium/neon laser was coupled temporarily to the distal end of the fiber to align the return fluorescence into the monochrometer slit.
A reference channel was constructed with 0.5 m of multimode step-index optical fiber (100-m core, 10-m cladding, and 120-m total diameter) with polyimide coating (Superguide G, SFS100/100T, Fiberguide) placed 5 mm from the lamp housing leading to a photomultiplier tube (1P28B22, RCA) operated at Ϫ650 V dc (Pacific Instruments). The photomultiplier tube output was measured with a high-impedance digital voltmeter.
Fluorescence measurements of solution-phase reactions were made with the fiber-optic instrument by submerging the distal end of the bare fiber into test samples. The fluorescence was determined for each reagent system contained in a 15 ϫ 75 mm vial with constant mechanical stirring.
reagents All chemicals were reagent grade except where indicated. Distilled deionized water was used throughout. Human cardiac myoglobin (98ϩ% pure by sodium dodecyl sulfate electrophoresis, Fortron Bioscience) was diluted in pH 7.4 phosphate-buffered saline (PBS 4 ; 10 mmol/L sodium phosphate and 150 mmol/L sodium chloride) and stored at 4°C until use.
Human hemoglobin was isolated from a hemolysate prepared from a fresh 100% hemoglobin A whole-blood sample collected in EDTA. The sample was centrifuged (1500g for 10 min), and the supernatant and buffy coat were discarded. A 2-mL cell pellet was washed twice with 4 mL of 9 g/L sodium chloride solution, and both supernatants were discarded. Erythrocytes were lysed by adding 1 mL of deionized water to the remaining pellet, followed by vortex-mixing and freezing at Ϫ70°C overnight. The sample was thawed and centrifuged to pellet cellular debris, and the supernatant was transferred to a capped cryovial for storage at Ϫ20°C. The final hemoglobin concentration was 2.3 mmol/L (148 g/L) (Cell-Dyn; Abbott Diagnostics). Hemolysate (9 mL) was diluted in 20.0 mL of PBS to give a final concentration of 1 mmol/L (66 mg/L).
purification of anti-myoglobin antibody and conjugation to cascade blue Five monoclonal IgG 1 myoglobin antibody clones were evaluated for use in the sensor. Antibody clones were each purified by Protein A chromatography (Immunopure IgG, Pierce) and dialyzed in a 12 000-Da cutoff cellulose membrane against triplicate changes of 1 L of PBS. The final postdialysis antibody concentration was ϳ1.1 g/L as calculated from the molar absorptivity, 2.1 ϫ 10 5 L mol Ϫ1 cm Ϫ1 at 280 nm [17] . Antibody purity was confirmed by observation of a single electrophoresis band for each clone with both 7.0% homogeneous and 8 -25% gradient polyacrylamide gels with Coomassie Blue staining (PhastGel, Pharmacia Biotech).
After purification, antibodies were conjugated to Cascade Blue (Molecular Probes). Cascade Blue acetylazide was obtained at 60% purity (by weight), and all molar ratios were adjusted accordingly. For the initial experiments to determine the optimum Cascade Blue:antibody molar ratio, Cascade Blue acetylazide (5 mg, 4.9 mol) was dissolved in 500 L of N,N-dimethylformamide (22,705-6, Aldrich) made anhydrous by drying over molecular sieves (20,860-4, 8 -12 mesh, Aldrich) to give a final concentration of ϳ9.9 mmol/L. Aliquots of five antibody clones were diluted to ϳ0.73 mol/L with PBS and dialyzed against 10 mmol/L pH 8.3 sodium bicarbonate buffer. Cascade Blue acetylazide was added at 27-, 135-, 675-, and 1350-fold molar excess (dye:antibody) to 1 mL of each antibody solution and incubated for 4 h at room temperature. Freshly prepared hydroxylamine (10 L of 15 mol/L reagent in pH 8.3 bicarbonate buffer) was then added to each labeled antibody solution to stop the reaction and remove labile intermediates from tyrosine, serine, threonine, and histidine. The solution was incubated for an additional 30 min at ambient temperature. The reaction mixture containing labeled antibody was dialyzed in triplicate against 1 L of PBS over 48 h at 4°C.
For all subsequent experiments, the labeling procedure was modified by increasing the Cascade Blue and antibody concentrations to reduce azide hydrolysis. Each antibody concentration was increased to 7.3 mol/L and Cascade Blue acetylazide was increased to 16.5 mmol/L for a fluorophore:antibody molar ratio of 823. The reaction mixture was incubated for 4 h, after which hydroxylamine was added to stop the reaction, diluted to 1 mL total volume with PBS, and dialyzed as described above. Because Cascade Blue absorbs light at 280 nm, the final antibody concentration (ϳ5 mol/L) was calculated from total nitrogen content. Cascade Blue concentration was determined from its molar absorptivity, 28 000 L mol Ϫ1 cm Ϫ1 at 376 nm [18] . measurement of cascade blue antibody reaction with myoglobin Typically, 10 L of ϳ7.3 mol/L Cascade Blue-labeled antibody was added to 990 L of PBS to give a 73 nmol/L solution. The fluorescence was measured at 425 nm, and 10-L aliquots of 4.0 mol/L myoglobin were added. The fluorescence quench was measured after at least 30 min of incubation after each myoglobin addition. For interference evaluation, hemoglobin was substituted for myoglobin.
preparation of aminoethylacrylamide
Aminoethylacrylamide was synthesized for covalent attachment to antibodies by a modified procedure for coupling diazonium salts to proteins [19, 20] . Ethylenediamine (15 mmol) (24,072-9, Aldrich) was added to 50 mL of dioxane/water (500 mL/L), adjusted to pH 8.5 with 3 mol/L HCl, and chilled to 4°C. Acryoyl chloride (16 mmol) (A2,410-9, Aldrich) was diluted in 30 mL of chloroform that was prechilled to 4°C. The acryoyl chloride solution was added slowly (ϳ2 mL/min) with a dropping funnel to the ethylenediamine solution while the pH was maintained between 8 and 8.5 with 3 mol/L sodium hydroxide with constant stirring in an ice bath. After 2 h, the aqueous phase was concentrated by vacuum evaporation, and the remaining slurry was redissolved in deionized water. Particulates were removed by centrifugation at 1000g for 15 min, and the supernatant was lyophilized and collected. Recovery of aminoethylacrylamide-HCl was ϳ10 mmol, giving Ͼ65% yield.
conjugation of anti-myoglobin antibody to aminoethylacrylamide
Cascade Blue-labeled antibody was dialyzed against 1 L of PBS adjusted to pH 4.7. Antibody (1 mL, containing ϳ7 nmol) was reacted at 4°C with 10 mol of aminoethylacrylamide-HCl, 50 mol of 1-(3-dimethylaminopropyl)-3ethylcarbodiimide (16,146-2, Aldrich), and 50 mol of N-hydroxysuccimide (H 7377, Sigma). The pH of the reaction mixture was readjusted to 4.5, and the solution was incubated at 4°C for 24 h, followed by dialysis in 12 000-Da-cutoff cellulose tubing against quadruplicate changes of 1 L of PBS. The final antibody concentrations were assumed to be equivalent to the starting material because there was negligible volume change during dialysis.
The effect of the aminoethylacrylamide conjugation on antibody binding was determined for three clones on the basis of the fluorescence quench after the addition of myoglobin. Each clone was diluted to ϳ73 nmol/L by the addition of 10 L of labeled antibody to a 1 ϫ 1 cm quartz cuvette containing 990 L of PBS. The fluorescence was measured in a conventional fluorometer after the addition of ten 10-L aliquots of 4.0 mol/L myoglobin, allowing at least 30 min between additions to reach equilibrium.
determination of nonspecific fluorescence quench
Monoclonal theophylline antibody (Beckman Instruments), bovine serum albumin (Sigma), and two monoclonal myoglobin antibody clones were each diluted to 1.1 g/L in PBS. Aliquots (300 L) of each protein solution and a PBS control were simultaneously labeled with 100 L of 16.5 mmol/L Cascade Blue acetylazide as described above. The solutions were dialyzed separately against triplicate changes of 1 L of PBS. The decrease in fluorescence was measured after the addition of 10-L aliquots of 4.0 mol/L myoglobin to 990 L of PBS containing 10 L of each Cascade Blue-labeled protein.
polyacrylamide gel preparation
Polyacrylamide gels were prepared from aqueous stock solutions of acrylamide (14,866-0, electrophoresis grade, Aldrich) and N,NЈ-methylenebisacrylamide (BIS; 14-832-6, electrophoresis grade, Aldrich). Where indicated, aminoethylacrylamide conjugated to myoglobin antibody was substituted for BIS to achieve the total desired net concentration of acrylamide incorporated into the gel. Acrylamide stock solutions were stored at 4°C and used within 2 weeks to limit hydrolysis of acrylic acid. Ammonium persulfate (24,861-4, ACS grade, Aldrich) free radical generator was prepared immediately before use as a 100 g/L solution in deionized water. Polyacrylamide gels were prepared by the addition of 209 L of stock acrylamide/BIS solution, 350 L of deionized water, 625 L of pH 7.4 PBS, and 9 L of ammonium persulfate. The solutions were deoxygenated with dry nitrogen for 30 s at room temperature, followed by the addition of 3 L of 6.63 mol/L N,N,NЈ,NЈ-tetramethylethylenediamine (T2,250-0, Aldrich) to catalyze the reaction.
The optimal acrylamide/BIS-acrylamide gel composition was determined on the basis of differential diffusion of myoglobin and hemoglobin in 3-mm-deep Ouchterlony diffusion gels cast in Petri dishes. Wells (2-mm diameter) were made at four locations on the plate and filled with 2 L of 640 mg/L myoglobin or hemoglobin. The radial diffusion of myoglobin and hemoglobin was measured after a 24-h incubation at room temperature.
sensor construction
Sensors were constructed with two glass capillary tubes surrounding an optical fiber, as shown in Fig. 2 . A 45-mm-long, 5-L capillary tube (Drummond Scientific) was fixed with cyanoacrylate adhesive inside a 50-mmlong, 25-L capillary tube, leaving a 5-mm cavity at the distal end of the tubes. The sensor cavity was immersed in a 5.3% polyacrylamide solution containing ϳ7 nmol/L Cascade Blue-antibody (0.05 volume fraction) immediately after the addition of tetramethylethylenediamine. The distal end of a prepared optical fiber was inserted through the lumen 3 mm beyond the end of the inner capillary and fixed with silicone adhesive at the proximate capillary end. The outer capillary provided a repro-ducible template for the polyacrylamide gel and provided protection against mechanical disruption of the fiber in the soft gel matrix. Sensors were incubated at room temperature for 1 h to ensure complete polymerization within the gel cavity. The sensors were incubated overnight at 4°C in PBS to rinse adsorbed antibodies from the gel and then stored at 4°C in PBS in a sealed tube until used.
measurement of sensor response
Sensors were operated at room temperature in a covered vial. Each sensor was initially equilibrated in 500 mL of PBS for 5 h at room temperature to ensure signal stability. Fluorescence measurements were taken periodically and recorded vs time. Sensor response was determined after typical additions of 5-10 L of stock myoglobin or hemoglobin to 1 mL of PBS to give the desired concentrations. The sensor fluorescence was measured until maximum quench was obtained. The sensor response was determined as the slope of fluorescence vs time and as the total amplitude of fluorescence quench measured in counts per second (cps). After maximum quench was achieved, sensors were transferred to PBS or to a solution of unlabeled myoglobin antibody in PBS to effect a zero concentration of free myoglobin in the solution.
Results
The design of the chemical transduction system utilized a fluorescently labeled monoclonal antibody as a molecular recognition element to concentrate myoglobin close to the fiber surface. The signal was derived from fluorescence energy transfer between the fluorescence donor, Cascade Blue, conjugated to the antibody and the myoglobin heme group that served as the energy acceptor. Fig. 3 shows the absorbance and emission spectra for myoglobin and Cascade Blue. The high molar absorptivity of myoglobin at 418 nm, 12.8 ϫ 10 4 L mol Ϫ1 cm Ϫ1 , and good spectral overlap with the emission spectrum of Cascade Blue enabled effective nonradiative energy transfer when the two molecules were geometrically proximate after antibody binding to myoglobin. Antibody binding was monitored by the quench of Cascade Blue fluorescence at 425 nm.
Optimal labeling conditions were critical in achieving the maximum change in fluorescence signal per unit of myoglobin. Fig. 4 shows the fluorescence quench obtained after addition of myoglobin to antibody labeled with 27to 1350-fold molar excess Cascade Blue. A molar ratio of 675 or greater gave maximum fluorescence quench. No increase in maximum quench was obtained by labeling at larger molar ratios, presumably because all Cascade Blue conjugation sites with geometric positions capable of energy transfer were occupied. Subsequent conjugations were performed at higher antibody concentrations with 823-fold molar excess Cascade Blue. These conditions increased the signal change per unit of myoglobin ϳ2fold, presumably because of improved fluorophore conjugation efficiency.
The optimal labeling condition for achieving the maximum fluorescence response range of the chemical transduction system required empirical determination for each antibody clone. Fig. 5 shows the total fluorescence quench at three myoglobin concentrations for five antibody clones labeled with the same molar ratios of Cascade Blue. Antibody G gave the greatest signal change over the largest range of myoglobin concentrations. Figure 6 shows the reversibility of the response of the sensor chemistry in solution phase. When myoglobin was added to a labeled antibody solution, it bound rapidly to antibody and quenched the Cascade Blue fluorescence. As more myoglobin was added, additional quenching was observed. At approximately equimolar quantities of antibody and myoglobin, a stable signal was observed (90 -100 min) and we added a 9-fold excess of unlabeled myoglobin antibody from a different clone. The unlabeled antibody rapidly bound any free myoglobin in solution and scavenged any myoglobin that dissociated from the labeled antibody. Thus, the Cascade Blue:antibody:myoglobin dissociation reaction was observed as an increase in fluorescence that remained stable for 1 h. The dissociation reaction occurred in ϳ10 min in solution phase. Figure 7 shows nonspecific fluorescence change attributable to inner filter absorption from solution phase of myoglobin after addition to Cascade Blue-labeled theophylline monoclonal antibody, Cascade Blue-labeled albumin, and Cascade Blue hydrolyzed in buffer. The inner filter absorption did not influence the fluorescence quench for specific binding of myoglobin to myoglobin antibody.
Hemoglobin was evaluated as a potential interferent in the myoglobin measurement system. Fig. 8 shows the results for addition of hemoglobin to several Cascade Blue-labeled myoglobin antibodies and Cascade Blue in buffer. All of the myoglobin antibodies showed hemoglobin interference. The minimum fluorescence response to hemoglobin was observed with antibody D, but this antibody also had the poorest response to myoglobin (Fig.  5 ). Antibody G had the largest quench response to myoglobin and hemoglobin. The fluorescence quench with Cascade Blue in buffer was minimal, suggesting no inner filter effect. The quench observed with hemoglobin appeared to represent cross-reactivity in the myoglobinantibody binding reaction. Consequently, the sensor design required a physical separation barrier to restrict hemoglobin access from the antibody reaction area.
Polyacrylamide gel was evaluated as a medium to immobilize Cascade Blue-labeled antibody at the distal end of an optical fiber and to restrict access of, and thus potential interference from, large-molecular-mass matrix components such as hemoglobin. Table 1 shows the radial diffusion of myoglobin and hemoglobin in various polyacrylamide gels. Gels prepared at Ͻ3.5% total acrylamide did not polymerize to a consistency rigid enough for use in the sensor. Gels prepared at acrylamide:BIS molar ratios of 75 and 100 gave the maximum diffusion of myoglobin with limited diffusion of hemoglobin. The 5.3% gel with an acrylamide:BIS molar ratio of 75 was used in all subsequent experiments because the lower gel concentration should enable faster diffusion of myoglobin to the sensing area.
A Cascade Blue-(antibody-aminoethylacrylamide) conjugate was covalently incorporated into the polyacrylamide gel to eliminate the possibility of Cascade Bluelabeled antibody leaching from the polymer matrix. Table  2 shows the effect on the antibody binding after conjugation of aminoethylacrylamide to Cascade Blue-labeled antibody. The solution phase fluorescence quench was slightly decreased for aminoethylacrylamide-labeled antibodies compared with non-acrylamide-labeled Cascade Blue-antibody controls. However, the labeling process did not substantially reduce the performance of the detection chemistry. Table 3 presents sensor responses when antibodies at the same concentrations were covalently attached to and entrapped in the polyacrylamide matrix. The total fluorescence response of sensors prepared with covalently attached antibody was less than that of the entrapped design. The rate of signal change with antibody covalently bound to the gel was about half the rate observed with the entrapped design, suggesting decreased relative diffusion of myoglobin through the gel with covalently attached antibody. In the entrapped configuration, the mean total quench was about the same at both myoglobin concentrations, but the rate of signal change was concentrationdependent. These observations suggest that diffusion into the gel matrix continued until all accessable antibody was bound to myoglobin at equilibrium.
myoglobin sensor performance
The total fluorescence for an intact sensor assembled with antibody labeled with 823-fold molar excess Cascade Blue was ϳ37 000 cps. The background signal for the fiber-optic fluorometer was ϳ15 000 cps for a bare fiber submerged in deionized water and 16 500 cps for a sensor constructed with polyacrylamide without Cascade Bluelabeled antibody. Two different sensors, prepared with antibodies C and G, had fluorescence signals at 24 h that were within 150 cps of the starting fluorescence. These results indicated that entrapped or polymerized Cascade Blue-labeled antibodies were equally retained in the 5.3% polyacrylamide gel matrix. Conjugation of antibody in the polyacrylamide gel reduced performance, was not necessary to prevent leaching, and was not investigated further. Figure 9 shows a sensor's response to myoglobin and hemoglobin. The sensor had a stable response with Ϯ50 cps (1.5%) noise in buffer between 0 and 80 min. Stabilization after the myoglobin additions was also Ϯ50 cps between 120 -170 min and 300 -420 min. No fluorescence quench was observed with hemoglobin at a concentration of 93 nmol/L, indicating the effectiveness of the polyacrylamide gel as a permeability barrier to the larger molecular mass protein. The sensor had a 200 cps response at 20 nmol/L (330 g/L) myoglobin and an additional 400 cps fluorescence decrease at 190 nmol/L (3.1 mg/L). A reversible response was not observed when the sensor was removed from the myoglobin solution and transferred to buffer containing 730 nmol/L unlabeled myoglobin antibody (90-fold molar excess to that in the sensor). This experiment was repeated with a different sensor that had a 50 cps quench (barely discernible from the baseline noise) when immersed in 5 nmol/L myoglo- Antibodies were labeled with 823-fold molar excess Cascade Blue. Sensors were equilibrated in buffer at least 2 h before bolus additions of myoglobin to the indicated final concentrations. Results shown are the average of five replicates for the entrapped antibody at 185 nmol/L myoglobin and of two replicates for the other conditions. bin and a similar 600 cps quench in 190 nmol/L myoglobin. This sensor also did not have a reversible response when placed into a 0 concentration myoglobin solution. The limit of detection for the sensor was ϳ5 nmol/L (83 g/L), and incremental fluorescence responses to incremental increases in myoglobin concentration were observed.
In Fig. 9 the sensor response time to reach a stable signal was 20 min at 20 nmol/L. At 190 nmol/L the response time was between 50 and 135 min but cannot be further defined because of the lack of observations past 50 min. Three other sensors measured concentrations of 190 -353 nmol/L with an average response time of 60 min (range 48 -66 min).
Discussion
The myoglobin sensor demonstrates technical feasibility for a self-contained fiber-optic immunosensor to measure a large-molecular-mass protein analyte. A fluorescence energy transfer transduction system was developed with Cascade Blue-labeled myoglobin antibody as the fluorescent energy donor and the intrinsic heme group of myoglobin as the energy acceptor. The labeled-antibody detection system was entrapped in a polyacrylamide matrix at the distal end of a flexible optical fiber but retained adequate molecular mobility for antigen binding. The polyacrylamide matrix also served to exclude the interfering protein hemoglobin from the sensor recognition and transduction chemistry.
The antibody was immobilized at the distal end of an optical fiber in a geometric configuration that provided a self-contained sensor unit. Polyacrylamide was selected as the immobilization medium because of its flexibility in creating different pore sizes to include or exclude molecules over a relatively large molecular-mass range, its polymerization at physiological pH to preserve the integrity of the antibody, and its low adsorption of proteins.
The gel pore size was adjusted to retain the fluorescently labeled antibody (150 000 Da) in a reactive configuration, prevent the diffusion of the interferent hemoglobin (64 500 Da), and allow the diffusion of myoglobin (16 500 Da) to the sensing area with an usable response time.
Hemoglobin was a good test molecule for high-molecularmass interferents because its size is similar to albumin and because it cross-reacts with the antibody-based fluorescence transduction chemistry. Thus the sensor response provided a sensitive indicator of the effectiveness of the gel entrapment design to prevent interference from molecules similar in size to or larger than hemoglobin. Specific serum and blood interferents would need to be tested in further development of this design, but one would expect the physical barrier to hemoglobin to apply similarly to other proteins and to cells.
The thickness of the gel layer was selected to allow adequate labeled antibody for a measurable fluorescence signal while permitting diffusion of myoglobin analyte into the optically interrogated region of the sensor. Simple entrapment of antibody in the polyacrylamide effectively retained antibody in the sensor region and produced a stable fluorescence signal. Covalent attachment of antibody to the polyacrylamide matrix was not required and somewhat degraded the sensor response. However, covalent attachment is feasible and provides another means for further optimization of the gel and for extension to other analytes.
The fiber-optic sensor was stable in buffer and showed a concentration-dependent fluorescence response to myoglobin. The slower antibody response in a sensor compared with solution-phase reactions was likely a result of slower diffusion of the protein analyte through the polyacrylamide matrix. It appears that myoglobin diffused into the sensing region at a rate controlled by both the gel pore size and the concentration gradient from bulk solution into the gel. Because antibody in the gel did not functionally release myoglobin after binding, a nearly constant concentration gradient was maintained until myoglobin binding reached an equilibrium with available antibody binding sites.
The analytical lowest detection limit of the current sensor configuration was marginal for measurement of myoglobin near the clinical decision limit after a myocardial infarction (5 nmol/L; 83 g/L) but consistently showed a measurable signal at 20 nmol/L (330 g/L). The sensor stability was adequate for an analyte such as myoglobin that has clinically useful concentration increases for ϳ8 h after a myocardial infarction. The antibody transduction system gave a reversible response to myoglobin binding in solution phase. This observation means that the antibody-myoglobin dissociation reaction is relatively fast [21] . However, the sensor configuration did not give a reversible fluorescence response to decreased myoglobin concentration after saturation of antibody binding sites. The lack of sensor reversibility may be a result of restricted movement of dissociated myoglobin within the gel matrix, preventing diffusion away from the antibody before rebinding. Lack of sensor reversibility could limit the utility for continuous monitoring of increases and decreases in concentration. However, a sensor that can respond to increases in concentration over time may have clinical value for measuring an analyte such as myoglobin that temporally increases after release from damaged cardiac tissue. Applications of this design for in vitro measurements are not limited by reversibility considerations.
Further development of the sensor is necessary for realistic measurements in a blood or serum matrix. Optimization of the polyacrylamide gel may achieve a faster response time and also permit adjustment of the dynamic range. Different immobilization strategies could make antibody more assessable to improve response time and allow a reversible response. Optical system enhancement by use of a laser source and pulsed operation could reduce background signal and enhance the fluorescence. Use of other fluorophores may also contribute to improvements in detection limits. Higher-affinity antibodies could be used but would negatively impact reversibility.
This fiber-optic immunosensor design demonstrates a miniature self-contained system capable of real-time protein analyte measurements. The limit of detection of the current configuration was ϳ5 nmol/L myoglobin. The sensor had a response time generally in the range of 20 -60 min. Improvements in both response time and dynamic range of concentration may be realized by further development of chemical, immobilization, and optical variables. The sensor design has barrier properties that may be suitable for whole-blood measurements.
